Cognition Therapeutics, Inc. announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will fund preclinical studies of two sigma-2 (s-2) receptor modulators in animal models of Parkinson's disease that will be led by Cognition Therapeutics' VP of research, Mary E. Hamby, Ph.D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | -3.52% | +0.52% | +3.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.78% | 79.68M | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson's Disease